About Sarepta Therapeutics
Sarepta Therapeutics is a company based in Cambridge (United States) founded in 1980. It operates as a HealthTech. The company has 1,370 employees as of December 31, 2024. Sarepta Therapeutics has completed 1 acquisition, including Myonexus Therapeutics. Sarepta Therapeutics offers products and services including Gene Therapy Treatments, RNA Platform Solutions, and Gene Editing Therapies. Sarepta Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 1370 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sarepta Therapeutics, Inc.
-
Annual Revenue
$1.9 B (USD)52.97as on Dec 31, 2024
-
Net Profit
$235.24 M (USD)0as on Dec 31, 2024
-
EBITDA
$271.97 M (USD)0as on Dec 31, 2024
-
Latest Funding Round
$400 M (USD), Post-IPO
Feb 28, 2020
-
Investors
Morgan Stanley
& 8 more
-
Employee Count
1370
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Sarepta Therapeutics
Sarepta Therapeutics is a publicly listed company on the NASDAQ with ticker symbol SRPT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Sarepta Therapeutics
Sarepta Therapeutics offers a comprehensive portfolio of products and services, including Gene Therapy Treatments, RNA Platform Solutions, and Gene Editing Therapies.
Gene therapies are developed for rare genetic diseases.
RNA technologies are utilized for rare disease treatments.
Gene editing is applied to address rare diseases.
People of Sarepta Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
115 people
Software Development Team
37 people
Senior Team
37 people
Operations Team
33 people
Product Management Team
32 people
Finance and Accounting
22 people
Sales and Marketing
11 people
Legal and Compliance
11 people
Unlock access to complete
Funding Insights of Sarepta Therapeutics
Investors in Sarepta Therapeutics
Sarepta Therapeutics has secured backing from 9 investors, including institutional investors. Prominent investors backing the company include Morgan Stanley, Credit Suisse and Baird.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Wealth management, investment advisory, and financial services are provided.
|
Locked | Locked | Locked | |
|
Financial services including wealth management and investment banking are offered by Baird.
|
Locked | Locked | Locked | |
|
Investment banking firm
|
Locked | Locked | Locked |
Investor details for Sarepta Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sarepta Therapeutics
Sarepta Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Myonexus Therapeutics.
Investment portfolio details for Sarepta Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Clinical stage gene therapy company developing treatments for Limb-girdle muscular dystrophy (LGMD)
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Sarepta Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Sarepta Therapeutics
Detailed financials for Sarepta Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sarepta Therapeutics Comparisons
Peer comparison for Sarepta Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sarepta Therapeutics
Sarepta Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
Detailed competitors of Sarepta Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sarepta Therapeutics
Complete news archive for Sarepta Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sarepta Therapeutics
Sarepta Therapeutics was founded in 1980 and raised its 1st funding round 26 years after it was founded.
Sarepta Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
As of Dec 31, 2024, the latest employee count at Sarepta Therapeutics is 1,370.
Annual revenue of Sarepta Therapeutics is $1.9B as on Dec 31, 2024.
Sarepta Therapeutics is engaged in the development of precision genetic medicines aimed at treating rare diseases. The company specializes in gene therapy, RNA technologies, and gene editing platforms. Focus areas include Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and Charcot-Marie-Tooth disease. Solutions are engineered to transform genetic understanding into effective treatments. Efforts are made to shorten drug development timelines and build significant gene therapy manufacturing capacity. Access and reimbursement models for innovative treatments are also rethought. The mission is centered on reclaiming futures impacted by rare diseases through relentless scientific advancement.
Sarepta Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Sarepta Therapeutics offers Gene Therapy Treatments, RNA Platform Solutions, and Gene Editing Therapies.
Yes, Sarepta Therapeutics is publicly traded on NASDAQ under the ticker symbol SRPT.
Sarepta Therapeutics has made 1 acquisition, including Myonexus Therapeutics.
Sarepta Therapeutics has 9 investors. Key investors include Morgan Stanley, Credit Suisse, Baird, HHS, and Needham.
The ticker symbol of Sarepta Therapeutics is SRPT on NASDAQ.